phase readout
saveNCT07633626: Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
RECRUITINGupdated 36m ago
community read0 votes
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo. Phase: . Conditions: Advanced ALK/ROS1-positive NSCLC, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Adenocarcinoma, ALK-positive Non-small Cell Lung Cancer (NSCLC), Cognitive Dysfunction, Depression
view source ↗
comments(0)
5-min edit window · permanent after that